BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011;37:291-9. [PMID: 21078547 DOI: 10.1016/j.ctrv.2010.10.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhao T, Li X, Chen Y, Du J, Chen X, Wang D, Wang L, Zhao S, Wang C, Meng Q, Sun H, Liu K, Wu J. Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp. Front Pharmacol 2022;13:914842. [DOI: 10.3389/fphar.2022.914842] [Reference Citation Analysis]
2 Escudero-Ortiz V, Domínguez-Leñero V, Catalán-Latorre A, Rebollo-Liceaga J, Sureda M. Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study. Pharmaceutics 2022;14:1216. [PMID: 35745789 DOI: 10.3390/pharmaceutics14061216] [Reference Citation Analysis]
3 Zhang M, Liu X, Chen Z, Jiang S, Wang L, Tao M, Miao L. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC–MS/MS for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 2021. [DOI: 10.1016/j.jpba.2021.114562] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Smy L, Sadler AJ, McMillin GA. Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization? Ther Drug Monit 2020;42:559-64. [PMID: 32697563 DOI: 10.1097/FTD.0000000000000771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhou M, Wang S, Guo J, Liu Y, Cao J, Lan X, Jia X, Zhang B, Xiao G, Wang W. RNA Interference Screening Reveals Requirement for Platelet-Derived Growth Factor Receptor Beta in Japanese Encephalitis Virus Infection. Antimicrob Agents Chemother 2021;65:e00113-21. [PMID: 33753340 DOI: 10.1128/AAC.00113-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xu H, Liu Q. Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors. Onco Targets Ther 2020;13:13345-55. [PMID: 33456310 DOI: 10.2147/OTT.S279998] [Reference Citation Analysis]
7 Goldstein MJ, Peters M, Weber BL, Davis CB. Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies. Clin Transl Sci 2021;14:536-43. [PMID: 33048459 DOI: 10.1111/cts.12902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Angaroni F, Graudenzi A, Rossignolo M, Maspero D, Calarco T, Piazza R, Montangero S, Antoniotti M. An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments. Front Bioeng Biotechnol 2020;8:523. [PMID: 32548108 DOI: 10.3389/fbioe.2020.00523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Iacuzzi V, Posocco B, Zanchetta M, Montico M, Marangon E, Poetto AS, Buzzo M, Gagno S, Buonadonna A, Guardascione M, Casetta B, Toffoli G. Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. PLoS One 2019;14:e0225225. [PMID: 31743371 DOI: 10.1371/journal.pone.0225225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
10 Abu Sammour D, Marsching C, Geisel A, Erich K, Schulz S, Ramallo Guevara C, Rabe JH, Marx A, Findeisen P, Hohenberger P, Hopf C. Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors. Sci Rep 2019;9:10698. [PMID: 31337874 DOI: 10.1038/s41598-019-47089-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
11 Cardoso E, Csajka C, Schneider MP, Widmer N. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clin Pharmacokinet 2018;57:1-6. [PMID: 28634655 DOI: 10.1007/s40262-017-0571-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
12 Fornasaro S, Bonifacio A, Marangon E, Buzzo M, Toffoli G, Rindzevicius T, Schmidt MS, Sergo V. Label-Free Quantification of Anticancer Drug Imatinib in Human Plasma with Surface Enhanced Raman Spectroscopy. Anal Chem 2018;90:12670-7. [PMID: 30350602 DOI: 10.1021/acs.analchem.8b02901] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
13 Ogata K, Kimura A, Nakazawa N, Suzuki M, Yanoma T, Ubukata Y, Iwamatsu K, Kogure N, Yanai M, Kuwano H. Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors. Digestion 2018;97:20-5. [DOI: 10.1159/000484102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema AD, Steeghs N. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients. Clin Pharmacokinet 2017;56:287-92. [PMID: 27435281 DOI: 10.1007/s40262-016-0439-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
15 Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat 2017;165:247-60. [DOI: 10.1007/s10549-017-4317-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 53] [Article Influence: 7.8] [Reference Citation Analysis]
16 Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. Drug-drug interactions with imatinib: An observational study. Medicine (Baltimore) 2016;95:e5076. [PMID: 27749579 DOI: 10.1097/MD.0000000000005076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
17 Altıntop MD, Temel HE, Sever B, Akalın Çiftçi G, Kaplancıklı ZA. Synthesis and Evaluation of New Benzodioxole- Based Thiosemicarbazone Derivatives as Potential Antitumor Agents. Molecules 2016;21:E1598. [PMID: 27879683 DOI: 10.3390/molecules21111598] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
18 Ben Ami E, Demetri GD. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opin Drug Saf. 2016;15:571-578. [PMID: 26865352 DOI: 10.1517/14740338.2016.1152258] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
19 Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer 2016;57:31-8. [PMID: 26851399 DOI: 10.1016/j.ejca.2015.12.029] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
20 Decosterd LA, Widmer N, Zaman K, Cardoso E, Buclin T, Csajka C. Therapeutic drug monitoring of targeted anticancer therapy. Biomark Med 2015;9:887-93. [PMID: 26333311 DOI: 10.2217/bmm.15.78] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
21 Pathak V, Colah R, Ghosh K. Tyrosine kinase inhibitors: New class of antimalarials on the horizon? Blood Cells Mol Dis 2015;55:119-26. [PMID: 26142327 DOI: 10.1016/j.bcmd.2015.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
22 McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy 2014;34:481-94. [PMID: 24877187 DOI: 10.1002/phar.1399] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
23 Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A. Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer 2014;50:2020-36. [DOI: 10.1016/j.ejca.2014.04.015] [Cited by in Crossref: 181] [Cited by in F6Publishing: 182] [Article Influence: 22.6] [Reference Citation Analysis]
24 Bardin C, Veal G, Paci A, Chatelut E, Astier A, Levêque D, Widmer N, Beijnen J. Therapeutic drug monitoring in cancer--are we missing a trick? Eur J Cancer 2014;50:2005-9. [PMID: 24878063 DOI: 10.1016/j.ejca.2014.04.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 6.8] [Reference Citation Analysis]
25 Angelini S, Ravegnini G, Fletcher JA, Maffei F, Hrelia P. Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. Pharmacogenomics 2013;14:941-56. [DOI: 10.2217/pgs.13.63] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
26 Manley PW, Blasco F, Mestan J, Aichholz R. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorganic & Medicinal Chemistry 2013;21:3231-9. [DOI: 10.1016/j.bmc.2013.03.038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
27 Al-Barrak J, Cheung WY. Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Support Care Cancer 2013;21:2351-7. [PMID: 23708821 DOI: 10.1007/s00520-013-1831-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
28 Petros WP, Younis IR, Ford JN, Weed SA. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 2012;32:920-31. [PMID: 23033231 DOI: 10.1002/j.1875-9114.2012.01117] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
29 Wallemacq P. Therapeutic drug monitoring of imatinib. Rev Bras Hematol Hemoter 2011;33:257-8. [PMID: 23049314 DOI: 10.5581/1516-8484.20110072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Anderson C, Plevin DM, McKinnon RA. Educating our students about pharmaceutical care for those living with cancer. Am J Pharm Educ 2012;76:119. [PMID: 23049094 DOI: 10.5688/ajpe767119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed Chromatogr 2013;27:335-42. [PMID: 22886846 DOI: 10.1002/bmc.2796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
32 Patel S. Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treatment Reviews 2012;38:467-72. [DOI: 10.1016/j.ctrv.2011.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
33 Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;23:2776-2781. [PMID: 22831984 DOI: 10.1093/annonc/mds198] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
34 Gundogdu E, Karasulu HY, Koksal C, Karasulu E. The novel oral imatinib microemulsions: physical properties, cytotoxicity activities and improved Caco-2 cell permeability. Journal of Microencapsulation 2012;30:132-42. [DOI: 10.3109/02652048.2012.704952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
35 Saponara M, Pantaleo MA, Nannini M, Biasco G. Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Target Oncol 2012;7:243-6. [PMID: 22592950 DOI: 10.1007/s11523-012-0221-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
36 Adekola K, Agulnik M. Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors. Curr Oncol Rep 2012;14:327-32. [DOI: 10.1007/s11912-012-0241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Steri R, Achenbach J, Steinhilber D, Schubert-Zsilavecz M, Proschak E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol 2012;83:1674-81. [PMID: 22414727 DOI: 10.1016/j.bcp.2012.02.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
38 Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012;125:640-645. [PMID: 22387451 DOI: 10.1016/j.ygyno.2012.02.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
39 Gasparini G, Longo R. The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets 2012;16:S7-S16. [DOI: 10.1517/14728222.2011.637921] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
40 Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf  J, Jaehde U. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles. Clinical Pharmacokinetics 2011;50:551-603. [DOI: 10.2165/11593320-000000000-00000] [Cited by in Crossref: 132] [Cited by in F6Publishing: 129] [Article Influence: 12.0] [Reference Citation Analysis]
41 Shieh MP, Mitsuhashi M, Lilly M. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol 2011;5:185-99. [PMID: 21792346 DOI: 10.4137/CMO.S6416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]